JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
JCR Pharmaceuticals Co., Ltd. has announced that MEDIPAL HOLDINGS CORPORATION is its largest shareholder with a 23.28% voting rights ownership. Both companies have been collaborating since 2017, focusing on leveraging MEDIPAL’s distribution and sales promotion strengths alongside JCR’s pharmaceutical R&D expertise. Recent agreements between the two companies include exclusive negotiation rights for MEDIPAL on global commercialization of JCR’s new drug candidates and licensing for the treatment of rare lysosomal storage diseases.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.
